2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimates
2017
Duration of neoadjuvant endocrine therapy and breast cancer outcomes.
Mougalian S, Soulos P, Lannin D, Pusztai L, Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer outcomes. Journal Of Clinical Oncology 2017, 35: e12129-e12129. DOI: 10.1200/jco.2017.35.15_suppl.e12129.Peer-Reviewed Original ResearchNeoadjuvant endocrine therapyEndocrine therapyClinical stagePathologic stageNational Cancer Data BasePR-positive breast cancerHigher nodal stageNetwork cancer programsAdjuvant endocrine therapyMultiple comorbid conditionsBreast cancer outcomesPopulation of patientsType of surgeryPositive breast cancerSimilar response ratesNeoadjuvant chemotherapyUnderwent surgeryNodal stageComorbid conditionsCancer outcomesLarge tumorsCancer programsBreast cancerOlder womenPatients